Navigation Links
India's Favorable and Progressive Regulatory Environment Causes Accelerated Growth of Max Neeman International's Regulatory Services
Date:10/11/2010

RESEARCH TRIANGLE PARK, N.C., Oct. 11 /PRNewswire/ -- India has evolved into a preferred destination for conducting clinical trials in large part because the Indian Regulatory bodies have created an environment which is focused on quality, transparency and protection in research activities.  Regulatory standards meet the requirements of ICH GCP, ICMR (Indian Council of Medical Research) and all the other regulatory bodies across the globe.

Owing to the favorable regulatory environment in India, Max Neeman's regulatory services have grown tremendously over the past few years and team members are qualified with more than 5 years of regulatory experience.  They specialize in providing the most effective regulatory assessment and strategy for timely submission and early approval. A systematic approach, rigorous follow-up and dedicated resources provide regulatory solutions for successful completion of the drug development cycle for clients.

The main regulatory body of India's government overseeing clinical trial research is the Drug Controller of India, Ministry of Health and Family Welfare, Government of India (DCGI).  DCGI is similar to the United States FDA who opened only the second non-USA office in India in 2009.  The Max Neeman team is updated with the all the recent and upcoming regulatory reforms initiated by the regulatory bodies in India and has the relationships to liaise with them effectively.

Based on each client's requirements, the regulatory team helps in developing:

  • regulatory strategy per client's requirements
  • regulatory submission and approval for initiating the trial
  • a review and evaluation of the pre-clinical data to provide step wise assistance in responding to questions by a regulatory body

Max Neeman will continue to maintain a strong regulatory team in support of India's progressive regulatory environment and the client's needs.

About Max Neeman International

Max Neeman International is a leading India-based CRO. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
2. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
3. Hospira Receives Favorable Court Decision on Eloxatin(R)
4. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
5. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
6. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
7. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
8. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
9. OXPEKK-IG Device Viking Gains Regulatory Approval in Korea
10. Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America
11. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... NEW YORK , February 28, 2017 ... lined up for assessment are the following equities: ZIOPHARM Oncology ... AUPH ), Arena Pharmaceuticals Inc. (NASDAQ: ... ). These companies belong to the Healthcare sector, which was ... the NYSE Health Care Index declining less than 0.1%, while ...
(Date:2/27/2017)... , Feb. 27, 2017 AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... today the U.S. Food and Drug Administration (FDA) ... under section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil ... patients with moderate-to-severe acute pain in a medically ...
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program ... of his grandfather, “Hire for attitude. Train for skill.” , In keeping with this ... Jevohn Miller as a salesman. Zamzow is hoping to replicate the practice throughout the ...
(Date:2/24/2017)... MA (PRWEB) , ... February 24, 2017 , ... ... replacement (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) ... fusion (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):